Elpis Hatziagorou1, Annalisa Orenti2, Pavel Drevinek3, Nataliya Kashirskaya4, Meir Mei-Zahav5, Kris De Boeck6. 1. Cystic Fibrosis Unit, Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece. Electronic address: hatziagorou@auth.gr. 2. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address: annalisa.orenti@unimi.it. 3. Department of Medical Microbiology, Faculty of Medicine, Motol University Hospital, Prague, Czech Republic. Electronic address: pavel.drevinek@Lfmotol.cuni.cz. 4. Department of Genetic Epidemiology (Cystic Fibrosis Group), Federal State Budgetary Institution «Research Centre for Medical Genetics», Moscow, Russia. 5. Tel Aviv University, Tel Aviv, Israel. Electronic address: meir_zahav@clalit.org.il. 6. Pediatric Pulmonology, Department of Pediatrics, University of Leuven, Leuven, Belgium. Electronic address: christiane.deboeck@uzleuven.be.
Abstract
BACKGROUND: Monitoring changes in the epidemiology of cystic fibrosis (CF) pathogens is essential for clinical research, quality improvement, and clinical management. METHODS: We analyzed data reported to the European Cystic Fibrosis Society Patient Registry (ECFSPR) from 2011 to 2016 to determine the overall and the age-specific annual prevalence and incidence of selected CF pathogens and their trends during these years. The ECFSPR collects data on three chronic infections: Pseudomonas aeruginosa (PsA), Burkholderia cepacia complex Species (BCC) and Staphylococcus aureus (SA), as well as on the occurrence of non-tuberculous mycobacteria (NTM) and Stenotrophomonas maltophilia (SM). The same analyses were performed for different country groups, according to their gross national income (GNI). RESULTS: The pathogens with the highest prevalence were SA and PsA, with prevalence, in 2016, equal to 38.3% and 29.8% respectively, followed by SM (8.1%). The pathogens with the lowest prevalence were NTM (3.3%) and BCC (3.1%). The overall prevalence and incidence significantly decreased for PsA; they also decreased for BCC, while they increased significantly for SA. The overall prevalence of NTM and SM increased significantly. The most considerable prevalence changes were observed for PsA, which decreased across all income country groups and all age strata (with the exception of 0-1 years) The prevalence and incidence of pathogens differed significantly according to GNI. CONCLUSIONS: The epidemiology of CF pathogens in Europe has changed; epidemiologic data differ significantly among countries with different socio-economic status. The causes of these observations are multifactorial and include improvements in clinical care and infection control.
BACKGROUND: Monitoring changes in the epidemiology of cystic fibrosis (CF) pathogens is essential for clinical research, quality improvement, and clinical management. METHODS: We analyzed data reported to the European Cystic Fibrosis SocietyPatient Registry (ECFSPR) from 2011 to 2016 to determine the overall and the age-specific annual prevalence and incidence of selected CF pathogens and their trends during these years. The ECFSPR collects data on three chronic infections: Pseudomonas aeruginosa (PsA), Burkholderia cepacia complex Species (BCC) and Staphylococcus aureus (SA), as well as on the occurrence of non-tuberculous mycobacteria (NTM) and Stenotrophomonas maltophilia (SM). The same analyses were performed for different country groups, according to their gross national income (GNI). RESULTS: The pathogens with the highest prevalence were SA and PsA, with prevalence, in 2016, equal to 38.3% and 29.8% respectively, followed by SM (8.1%). The pathogens with the lowest prevalence were NTM (3.3%) and BCC (3.1%). The overall prevalence and incidence significantly decreased for PsA; they also decreased for BCC, while they increased significantly for SA. The overall prevalence of NTM and SM increased significantly. The most considerable prevalence changes were observed for PsA, which decreased across all income country groups and all age strata (with the exception of 0-1 years) The prevalence and incidence of pathogens differed significantly according to GNI. CONCLUSIONS: The epidemiology of CF pathogens in Europe has changed; epidemiologic data differ significantly among countries with different socio-economic status. The causes of these observations are multifactorial and include improvements in clinical care and infection control.
Authors: Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo Journal: JAC Antimicrob Resist Date: 2022-05-05
Authors: Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli Journal: Antibiotics (Basel) Date: 2021-03-22
Authors: Marie K Wieneke; Felix Dach; Claudia Neumann; Dennis Görlich; Lena Kaese; Theo Thißen; Angelika Dübbers; Christina Kessler; Jörg Große-Onnebrink; Peter Küster; Holger Schültingkemper; Bianca Schwartbeck; Johannes Roth; Jerzy-Roch Nofer; Janina Treffon; Julia Posdorfer; Josefine Marie Boecken; Mariele Strake; Miriam Abdo; Sophia Westhues; Barbara C Kahl Journal: mSphere Date: 2021-06-23 Impact factor: 4.389